Celgene to Acquire Juno for $9 Billion, Picking Up Potential CAR T-cell Lymphoma Therapies – Lymphoma News Today
Lymphoma News Today |
Celgene to Acquire Juno for $9 Billion, Picking Up Potential CAR T-cell Lymphoma Therapies
Lymphoma News Today Celgene will buy Juno Therapeutics for $9 billion in a deal that gives Celgene access to an experimental gene therapy for treating people with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. The acquisition, announced Jan. 22 … Here’s Why Fate Therapeutics Rose as Much as 18% TodayMotley Fool |
Madison.com |
Here’s What’s Driving Crispr Therapeutics AG Higher Today …
Madison.com Shares of Crispr Therapeutics AG (NASDAQ: CRSP), a start-up biotech using eponymous gene-editing technology to develop new therapies, popped 15.2% in early-morning trading on Tuesday. Shares have settled to a gain of 14.4% as of 12:10 p.m. EST after … Ipswich Investment Management Co. Inc. Takes $1.13 Million Position in Crispr Therapeutics AG (NASDAQ:CRSP)The Ledger Gazette Shares that proliferate your speculations: CRISPR Therapeutics AG (CRSP)The News Journal Analyst Upgrades – Crispr Therapeutics (NASDAQ:CRSP) Stock Gets Upgraded By SunTrust Banks from Hold to BuyMarket Exclusive Post Analyst –Norman Weekly –Aiken Advocate all 25 news articles » |